C A González1, F Megraud2, A Buissonniere2, L Lujan Barroso3, A Agudo3, E J Duell3, M C Boutron-Ruault4, F Clavel-Chapelon4, D Palli5, V Krogh6, A Mattiello7, R Tumino8, C Sacerdote9, J R Quirós10, E Sanchez-Cantalejo11, C Navarro12, A Barricarte13, M Dorronsoro14, K-T Khaw15, N Wareham15, N E Allen16, K K Tsilidis16, H Bas Bueno-de-Mesquita17, S M Jeurnink17, M E Numans18, P H M Peeters18, P Lagiou19, E Valanou20, A Trichopoulou20, R Kaaks21, A Lukanova-McGregor21, M M Bergman22, H Boeing22, J Manjer23, B Lindkvist24, R Stenling25, G Hallmans26, L M Mortensen27, K Overvad27, A Olsen28, A Tjonneland28, K Bakken29, V Dumeaux29, E Lund29, M Jenab30, I Romieu30, D Michaud31, T Mouw31, F Carneiro32, C Fenge33, E Riboli34. 1. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. Electronic address: cagonzalez@iconcologia.net. 2. INSERM U853, Bordeaux. 3. Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. 4. Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy, Villejuif; Paris South University, Villejuif, France. 5. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence. 6. Department of Preventive & Predictive Medicine, Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei TumoriMilan. 7. Department Of Clinical And Experimental Medicine, Federico Ii University, Naples. 8. Cancer Registry and Histopathology Unit, "Civile M.P. Arezzo" Hospital, Ragusa. 9. Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy. 10. Public Health and Participation Directorate, Health and Health Care Services Council, Asturias. 11. Andalusian School of Public Health, CIBER Epidemiología y Salud Pública (CIBERESP), Granada. 12. Department of Epidemiology, Murcia Health Council, CIBER Epidemiología y Salud Pública (CIBERESP) Murcia, Murcia. 13. Navarre Public Health Institute, CIBER Epidemiología y Salud Pública (CIBERESP), Pamplona. 14. Public Health Division of Gipuzkoa and Ciberesp, Basque Regional Health Department, San Sebastián, Spain. 15. Department of Public Health and Primary Care, University of Cambridge, Cambridge. 16. Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. 17. National Institute for Public Health and the Environment (RIVM), Bilthoven; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht (UMCU), Utrecht. 18. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 19. WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens. 20. Hellenic Health Foundation, Athens, Greece. 21. Department of Cancer Epidemiology, German Cancer Research Center, Heidelberg. 22. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Potsdam, Germany. 23. Department of Surgery, Skåne University Hospital Malmö, Lund University, Malmö. 24. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg. 25. Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden. 26. Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden. 27. Department of Epidemiology, School of Public Health, Aarhus University, Aarhus. 28. Danish Cancer Society, Institute of Cancer Epidemiology, Diet Cancer and Health, Copenhagen, Denmark. 29. Department of Community Medicine, University of Tromsø, Tromso, Norway. 30. International Agency for Research on Cancer (IARC-WHO), Lyon, France. 31. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. 32. Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Medical Faculty/HS João, Porto, Portugal. 33. Department of Clinical Pathology, Odense University Hospital, Odense, Denmark. 34. School of Public Health, St Mary's Campus, Imperial College London, London, UK.
Abstract
BACKGROUND: In epidemiological studies, Helicobacter pylori infection is usually detected by enzyme-linked immunosorbent assay (ELISA). However, infection can spontaneously clear from the mucosa during the progression of atrophy and could lead to substantial under-detection of infection and underestimation of its effect on gastric cancer (GC) risk. Antibodies detected by western blot are known to persist longer after the loss of the infection. METHODS: In a nested case-control study from the Eurogast-EPIC cohort, including 88 noncardia GC cases and 338 controls, we assessed the association between noncardia GC and H. pylori infection comparing antibodies detected by western blot (HELICOBLOT2.1) to those detected by ELISA (Pyloriset EIA-GIII(®)). RESULTS: By immunoblot, 82 cases (93.2%) were H. pylori positive, 10 of these cases (11.4%) were negative by ELISA and only 6 cases (6.8%) were negative by both ELISA and immunoblot. Multivariable odds ratio (OR) for noncardia GC comparing immunoglobulin G positive versus negative by ELISA was 6.8 [95% confidence interval (CI) 3.0-15.1], and by immunoblot, the OR was 21.4 (95% CI 7.1-64.4). CONCLUSIONS: Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC.
BACKGROUND: In epidemiological studies, Helicobacter pylori infection is usually detected by enzyme-linked immunosorbent assay (ELISA). However, infection can spontaneously clear from the mucosa during the progression of atrophy and could lead to substantial under-detection of infection and underestimation of its effect on gastric cancer (GC) risk. Antibodies detected by western blot are known to persist longer after the loss of the infection. METHODS: In a nested case-control study from the Eurogast-EPIC cohort, including 88 noncardia GC cases and 338 controls, we assessed the association between noncardia GC and H. pylori infection comparing antibodies detected by western blot (HELICOBLOT2.1) to those detected by ELISA (Pyloriset EIA-GIII(®)). RESULTS: By immunoblot, 82 cases (93.2%) were H. pylori positive, 10 of these cases (11.4%) were negative by ELISA and only 6 cases (6.8%) were negative by both ELISA and immunoblot. Multivariable odds ratio (OR) for noncardia GC comparing immunoglobulin G positive versus negative by ELISA was 6.8 [95% confidence interval (CI) 3.0-15.1], and by immunoblot, the OR was 21.4 (95% CI 7.1-64.4). CONCLUSIONS: Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC.
Authors: P H Nguyen; J Giraud; C Staedel; L Chambonnier; P Dubus; E Chevret; H Bœuf; X Gauthereau; B Rousseau; M Fevre; I Soubeyran; G Belleannée; S Evrard; D Collet; F Mégraud; C Varon Journal: Oncogene Date: 2016-05-09 Impact factor: 9.867
Authors: Jae Moon Yoon; Ki Young Son; Chun Sick Eom; Daniel Durrance; Sang Min Park Journal: World J Gastroenterol Date: 2013-02-14 Impact factor: 5.742
Authors: Antonio Agudo; Catalina Bonet; Núria Sala; Xavier Muñoz; Núria Aranda; Ana Fonseca-Nunes; Françoise Clavel-Chapelon; Marie Christine Boutron-Ruault; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Sara Grioni; J Ramón Quirós; Esther Molina; Carmen Navarro; Aurelio Barricarte; Saioa Chamosa; Naomi E Allen; Kay-Tee Khaw; H Bas Bueno-de-Mesquita; Peter D Siersema; Mattijs E Numans; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Rudof Kaaks; Federico Canzian; Heiner Boeing; Karina Meidtner; Mattias Johansson; Malin Sund; Jonas Manjer; Kim Overvad; Anne Tjonneland; Eiliv Lund; Elisabete Weiderpass; Mazda Jenab; Veronika Fedirko; G Johan A Offerhaus; Elio Riboli; Carlos A González; Paula Jakszyn Journal: Carcinogenesis Date: 2013-02-06 Impact factor: 4.944